CREBL2 Inhibitors
CREBL2 inhibitors are a diverse group of compounds that target a variety of signaling pathways intricately connected to the regulation of CREBL2 function. These inhibitors operate by disrupting the intracellular signaling cascades that CREBL2 may depend on for its activity within the cell, particularly those related to cell growth, proliferation, and stress responses. For instance, inhibitors of the mTOR pathway, such as LY294002 and Wortmannin, lead to a decrease in CREBL2 activity by hindering the PI3K/AKT/mTOR signaling axis, which is a critical route for relaying growth and survival signals within the cell. This pathway's inhibition results in a reduction of protein synthesis and other growth-related processes that CREBL2 may influence.
Similarly, compounds that inhibit the MAPK/ERK pathway, like U0126 and PD98059, would hinder CREBL2 activity by obstructing the pathway responsible for transmitting extracellular growth signals to the nucleus. By inhibiting MEK, the activation of ERK is prevented, which may be necessary for CREBL2's role in modulating gene expression in response to these signals. Additionally, inhibitors of stress-activated pathways, such as SB203580, which targets p38 MAP kinase, and SP600125, which inhibits JNK, would also lead to decreased CREBL2 activity by impairing the cell's ability to respond to stress stimuli that CREBL2 may be involved in managing.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTORC1 complex, leading to decreased protein synthesis and cell proliferation. Since CREBL2 activity is associated with cellular growth signals, inhibiting mTORC1 could reduce the activity of CREBL2 indirectly by limiting the cellular conditions necessary for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which interrupts the PI3K/AKT/mTOR pathway. This inhibition reduces the phosphorylation and activation of downstream targets including mTOR, which is involved in protein synthesis and cell survival that CREBL2 may be a part of. By inhibiting PI3K, the downstream effects would include reduced CREBL2 activity due to decreased protein synthesis capacity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which would impede the response to stress signals. CREBL2, being responsive to cellular stress, may have reduced activity when p38 MAPK is inhibited, as the stress-induced signaling necessary for CREBL2 activation would be compromised. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, like LY294002, and would therefore have a similar effect in reducing CREBL2 activity by inhibiting the PI3K/AKT/mTOR pathway, thereby decreasing protein synthesis and cell growth signals that CREBL2 may be involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. Inhibition of MEK would prevent the activation of ERK, resulting in decreased CREBL2 activity since CREBL2 may depend on the MAPK pathway for activation in response to growth signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which would suppress the JNK signaling pathway involved in stress responses and apoptosis. CREBL2, if involved in these pathways, would have decreased activity due to the inhibition of JNK-mediated signaling. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an ATP-competitive inhibitor of mTOR, which unlike rapamycin, inhibits both mTORC1 and mTORC2 complexes. The inhibition of these complexes would lead to a decrease in CREBL2 activity by broadly preventing the cellular growth conditions that CREBL2 relies on for its activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is another ATP-competitive mTOR inhibitor, targeting both mTORC1 and mTORC2. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent mTOR inhibitor that works against both mTORC1 and mTORC2 complexes. By inhibiting these complexes, Torin 1 would decrease CREBL2 activity indirectly by reducing the cellular signals required for CREBL2's function in growth and proliferation. | ||||||
SL 0101-1 | 77307-50-7 | sc-204287 sc-204287A sc-204287B sc-204287C sc-204287D | 1 mg 10 mg 25 mg 50 mg 100 mg | $200.00 $353.00 $772.00 $1230.00 $2070.00 | 3 | |
SL0101 is an inhibitor of RSK , which functions downstream of ERK. Inhibition of RSK would result in decreased CREBL2 activity as CREBL2 may rely on RSK for mediating its effects in response to growth and survival signals. | ||||||